FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110621750> ?p ?o ?g. }

• W2110621750 endingPage "92" @default.
• W2110621750 startingPage "2683" @default.
• W2110621750 abstract "Molecular antagonists of the inhibitor of apoptosis protein survivin have shown promise as novel anticancer strategies for triggering tumor cell apoptosis, dysregulating mitotic progression, and inhibiting tumor growth in preclinical models. However, how survivin couples to the cell death machinery has remained elusive, and the relevant cellular targets of survivin antagonists have not been completely elucidated.Human umbilical vein and dermal microvascular endothelial cells were infected with replication-deficient adenoviruses encoding survivin (pAd-Survivin), green fluorescent protein (pAd-GFP), or a phosphorylation-defective survivin Thr(34)-->Ala (pAd-T34A) dominant negative mutant. The effect of wild-type or mutant survivin was investigated on capillary network stability, endothelial cell viability, and caspase activation in vitro and on kinetics of tumor growth and development of angiogenesis in a breast cancer xenograft model in vivo. The cell death pathway initiated by survivin targeting was mapped with respect to cytochrome c release, changes in mitochondrial transmembrane potential, and apoptosome requirements using mouse embryonic fibroblasts deficient in Apaf-1 or caspase-9.Adenoviral transduction of endothelial cells with pAd-Survivin inhibited growth factor deprivation- or ceramide-induced apoptosis, reduced caspase-3 and -7 generation, and stabilized three-dimensional capillary networks in vitro. Conversely, expression of pAd-T34A caused apoptosis in umbilical vein and dermal microvascular endothelial cells and resulted in caspase-3 activity. Cell death induced by survivin targeting exhibited the hallmarks of mitochondrial-dependent apoptosis with release of cytochrome c and loss of mitochondrial transmembrane potential and was suppressed in Apaf-1 or caspase-9 knockout mouse embryonic fibroblasts. When injected in human breast cancer xenografts, pAd-T34A inhibited growth of established tumors and triggered tumor cell apoptosis in vivo. This was associated with a approximately 60% reduction in tumor-derived blood vessels by quantitative morphometry of CD31-stained tumor areas, and appearance of endothelial cell apoptosis by internucleosomal DNA fragmentation in vivo.Survivin functions as a novel upstream regulator of mitochondrial-dependent apoptosis, and molecular targeting of this pathway results in anticancer activity via a dual mechanism of induction of tumor cell apoptosis and suppression of angiogenesis." @default.
• W2110621750 created "2016-06-24" @default.
• W2110621750 creator A5009027988 @default.
• W2110621750 creator A5027775750 @default.
• W2110621750 creator A5040623212 @default.
• W2110621750 creator A5041485823 @default.
• W2110621750 creator A5052535761 @default.
• W2110621750 creator A5082346201 @default.
• W2110621750 date "2003-07-01" @default.
• W2110621750 modified "2023-10-03" @default.
• W2110621750 title "Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis." @default.
• W2110621750 cites W1492587973 @default.
• W2110621750 cites W1512072225 @default.
• W2110621750 cites W1533153036 @default.
• W2110621750 cites W1595083214 @default.
• W2110621750 cites W1616649922 @default.
• W2110621750 cites W1745634660 @default.
• W2110621750 cites W1870720170 @default.
• W2110621750 cites W1894077997 @default.
• W2110621750 cites W1966176339 @default.
• W2110621750 cites W1966521331 @default.
• W2110621750 cites W1981006523 @default.
• W2110621750 cites W1982715427 @default.
• W2110621750 cites W1985850927 @default.
• W2110621750 cites W198605181 @default.
• W2110621750 cites W1989394815 @default.
• W2110621750 cites W2028466368 @default.
• W2110621750 cites W2030943817 @default.
• W2110621750 cites W2034269086 @default.
• W2110621750 cites W2035523654 @default.
• W2110621750 cites W2036981368 @default.
• W2110621750 cites W2039791984 @default.
• W2110621750 cites W2042409437 @default.
• W2110621750 cites W2047143821 @default.
• W2110621750 cites W2049873418 @default.
• W2110621750 cites W2059421587 @default.
• W2110621750 cites W2059890691 @default.
• W2110621750 cites W2064580048 @default.
• W2110621750 cites W2103654270 @default.
• W2110621750 cites W2119241431 @default.
• W2110621750 cites W2120473562 @default.
• W2110621750 cites W2124895782 @default.
• W2110621750 cites W2125561041 @default.
• W2110621750 cites W2127479913 @default.
• W2110621750 cites W2135717924 @default.
• W2110621750 cites W2146787008 @default.
• W2110621750 cites W2149707499 @default.
• W2110621750 cites W2154795389 @default.
• W2110621750 cites W2163453798 @default.
• W2110621750 cites W2325774436 @default.
• W2110621750 cites W2395107753 @default.
• W2110621750 cites W348127839 @default.
• W2110621750 cites W54712678 @default.
• W2110621750 cites W95153881 @default.
• W2110621750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12855648" @default.
• W2110621750 hasPublicationYear "2003" @default.
• W2110621750 type Work @default.
• W2110621750 sameAs 2110621750 @default.
• W2110621750 citedByCount "66" @default.
• W2110621750 countsByYear W21106217502012 @default.
• W2110621750 countsByYear W21106217502013 @default.
• W2110621750 countsByYear W21106217502014 @default.
• W2110621750 countsByYear W21106217502015 @default.
• W2110621750 countsByYear W21106217502017 @default.
• W2110621750 countsByYear W21106217502018 @default.
• W2110621750 countsByYear W21106217502019 @default.
• W2110621750 countsByYear W21106217502021 @default.
• W2110621750 countsByYear W21106217502022 @default.
• W2110621750 countsByYear W21106217502023 @default.
• W2110621750 crossrefType "journal-article" @default.
• W2110621750 hasAuthorship W2110621750A5009027988 @default.
• W2110621750 hasAuthorship W2110621750A5027775750 @default.
• W2110621750 hasAuthorship W2110621750A5040623212 @default.
• W2110621750 hasAuthorship W2110621750A5041485823 @default.
• W2110621750 hasAuthorship W2110621750A5052535761 @default.
• W2110621750 hasAuthorship W2110621750A5082346201 @default.
• W2110621750 hasConcept C190283241 @default.
• W2110621750 hasConcept C2775975398 @default.
• W2110621750 hasConcept C2777408456 @default.
• W2110621750 hasConcept C2780394083 @default.
• W2110621750 hasConcept C28859421 @default.
• W2110621750 hasConcept C29311851 @default.
• W2110621750 hasConcept C31573885 @default.
• W2110621750 hasConcept C502942594 @default.
• W2110621750 hasConcept C55493867 @default.
• W2110621750 hasConcept C86803240 @default.
• W2110621750 hasConcept C95444343 @default.
• W2110621750 hasConceptScore W2110621750C190283241 @default.
• W2110621750 hasConceptScore W2110621750C2775975398 @default.
• W2110621750 hasConceptScore W2110621750C2777408456 @default.
• W2110621750 hasConceptScore W2110621750C2780394083 @default.
• W2110621750 hasConceptScore W2110621750C28859421 @default.
• W2110621750 hasConceptScore W2110621750C29311851 @default.
• W2110621750 hasConceptScore W2110621750C31573885 @default.
• W2110621750 hasConceptScore W2110621750C502942594 @default.
• W2110621750 hasConceptScore W2110621750C55493867 @default.
• W2110621750 hasConceptScore W2110621750C86803240 @default.
• W2110621750 hasConceptScore W2110621750C95444343 @default.

• next